GlassScriptPhysician profile
Stacy B Woods
NPI 1366560286
$2,125.97
in general payments reported to CMS, 2019-2025
15 companies · $660 in 2025
The $660 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $24.08 · 2023: $503 · 2024: $587 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $403.10 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $398.07 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $385.47 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $240.73 | 2023-2025 | Austedo, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $215.05 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $159.29 | 2023-2025 | Auvelity, Sunosi |
| Calliditas Therapeutics US INC. | $72.59 | 2024 | |
| Idorsia Pharmaceuticals US INC | $44.55 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $44.35 | 2019-2025 | Spravato |
| Allergan, INC. | $40.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $39.35 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $22.55 | 2019 | |
| Avanir Pharmaceuticals, INC. | $22.17 | 2019 | |
| Bausch Health US, LLC | $20.39 | 2025 | Wellbutrin |
| Lilly USA, LLC | $17.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.